SRR5088907
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.400
- G2M_CHECKPOINT+0.400
- HYPOXIA+0.400
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.300
- HEME_METABOLISM+0.300
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.300
- TGF_BETA_SIGNALING+0.300
- WNT_BETA_CATENIN_SIGNALING+0.300
- ANGIOGENESIS+0.200
- APOPTOSIS+0.200
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.400
- FATTY_ACID_METABOLISM-0.200
- INTERFERON_GAMMA_RESPONSE-0.200
- KRAS_SIGNALING_DN-0.200
- OXIDATIVE_PHOSPHORYLATION-0.200
- PROTEIN_SECRETION-0.200
- ADIPOGENESIS-0.100
- ALLOGRAFT_REJECTION-0.100
- IL6_JAK_STAT3_SIGNALING-0.100
- UNFOLDED_PROTEIN_RESPONSE-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG1297 | — | — | 0.721 |
| 2 | MNG471 | — | — | 0.717 |
| 3 | MNG1272 | — | — | 0.698 |
| 4 | TCGA-E2-A1LL-01A-11R-A144-07 | — | C | 0.697 |
| 5 | SRR2771207 | — | — | 0.697 |
| 6 | MNG336 | — | — | 0.697 |
| 7 | ERR2598207 | fetal | fetal | 0.689 |
| 8 | TCGA-85-7844-01A-11R-2125-07 | — | cohortSQ2 | 0.672 |
| 9 | SRR8613735 | — | E | 0.660 |
| 10 | TCGA-A7-A6VV-01A-22R-A33J-07 | — | E | 0.656 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.400 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.400 | Inavolisib | — uncovered |
| HYPOXIA | 0.400 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.300 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.300 | Temsirolimus | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.300 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.300 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.300 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.200 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.200 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.200 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.200 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.200 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.200 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.200 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.100 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.100 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.100 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.100 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.100 | Inavolisib | — uncovered |